| ［1］ |
Versluis JM，Long GV，Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade［J］.Nat Med，2020，26（4）： 475-484.
|
| ［2］ |
Liu J，Blake SJ，Yong MC，et al. Improved Efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease［J］.Cancer Discov，2016，6（12）： 1382-1399.
|
| ［3］ |
Schmid P，Cortes J，Dent R，et al. Event-free survival with pembrolizumab in early triple-negative breast cancer［J］.N Engl J Med，2022，386（6）： 556-567.
|
| ［4］ |
Schmid P，Cortes J，Pusztai L，et al. Pembrolizumab for early triple-negative breast cancer［J］.N Engl J Med，2020，382（9）： 810-821.
|
| ［5］ |
Schmid P，Cortés J，Dent RA，et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC： updated EFS results from the phase Ⅲ KEYNOTE-522 study［J］.Ann Oncol，2023，34： S1257.
|
| ［6］ |
Mittendorf EA，Zhang H，Barrios CH，et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer （IMpassion031）： a randomised，double-blind，phase 3 trial［J］.Lancet，2020，396（10257）： 1090-1100.
|
| ［7］ |
Cardoso F，O'Shaughnessy J，Liu Z，et al. Pembrolizumab and chemotherapy in high-risk，early-stage，ER（+）/HER2（-） breast cancer： a randomized phase 3 trial［J］.Nat Med，2025，31（2）： 442-448.
|
| ［8］ |
Loi S，Salgado R，Curigliano G，et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer： a randomized phase 3 trial［J］.Nat Med，2025，31（2）： 433-441.
|
| ［9］ |
Ignatiadis M，Bailey A，McArthur H，et al. Adjuvant atezolizumab for early triple-negative breast cancer： the ALEXANDRA/IMpassion030 randomized clinical trial［J］.JAMA，2025，333（13）： 1150-1160.
|
| ［10］ |
Chen L，Li H，Zhang H，et al. Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer： the CamRelief randomized clinical trial［J］.JAMA，2025，333（8）： 673-681.
|
| ［11］ |
Huober J，Barrios CH，Niikura N，et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer： primary results of the randomized phase Ⅲ IMpassion050 trial［J］.J Clin Oncol，2022，40（25）： 2946-2956.
|
| ［12］ |
Gianni L，Munzone E，Mansutti M，et al. Pathologic complete response （pCR） of neoadjuvant therapy with or without atezolizumab in HER2-positive，early high-risk and locally advanced breast cancer： APTneo Michelangelo randomized trial［J］.Cancer Res，2024，84（9 Suppl）： LBO1-02.
|
| ［13］ |
Loibl S，Untch M，Burchardi N，et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer： clinical results and biomarker analysis of GeparNuevo study［J］.Ann Oncol，2019，30（8）： 1279-1288.
|
| ［14］ |
Sharma P，Stecklein SR，Yoder R，et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer： NeoPACT phase 2 clinical trial［J］.JAMA Oncol，2024，10（2）： 227-235.
|
| ［15］ |
Yu Z. Tislelizumab： an effective treatment option for early-stage triple-negative breast cancer［J］.Transl Breast Cancer Res，2024，5： 5.
|
| ［16］ |
Bhardwaj PV，Abdou YG. The evolving landscape of immune checkpoint inhibitors and antibody drug conjugates in the treatment of early-stage breast cancer［J］.Oncologist，2023，28（10）： 832-844.
|
| ［17］ |
Cortes J，Cescon DW，Rugo HS，et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer （KEYNOTE-355）： a randomised，placebo-controlled，double-blind，phase 3 clinical trial［J］.Lancet，2020，396（10265）： 1817-1828.
|
| ［18］ |
He M，Hao S，Ma L，et al. Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer （NeoTENNIS）： a single-arm，phase Ⅱ study［J］.EClinicalMedicine，2024，74： 102700.
|
| ［19］ |
Wang C，Liu Z，Chen X，et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer： a single-arm phase Ⅱ trial［J］.Nat Commun，2023，14（1）： 6654.
|
| ［20］ |
Masuda N，Lee SJ，Ohtani S，et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy［J］.N Engl J Med，2017，376（22）： 2147-2159.
|
| ［21］ |
Tutt ANJ，Garber JE，Kaufman B，et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer［J］.N Engl J Med，2021，384（25）： 2394-2405.
|
| ［22］ |
Geyer CE Jr，Garber JE，Gelber RD，et al. Overall survival in the OlympiA phase Ⅲ trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk，early breast cancer［J］.Ann Oncol，2022，33（12）： 1250-1268.
|
| ［23］ |
Schmid P，Rugo HS，Adams S，et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable，locally advanced or metastatic triple-negative breast cancer （IMpassion130）： updated efficacy results from a randomised，double-blind，placebo-controlled，phase 3 trial［J］.Lancet Oncol，2020，21（1）： 44-59.
|
| ［24］ |
Ren XY，Song Y，Wang J，et al. Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer： a retrospective study of 440 patients［J］.Front Oncol，2021，11： 570623.
|
| ［25］ |
Miao K，Zhang L. Pathogenesis，pathological characteristics and individualized therapy for immune-related adverse effects［J］.Chin Med J Pulm Crit Care Med，2023，1（4）： 215-222.
|
| ［26］ |
Postow MA，Sidlow R，Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade［J］.N Engl J Med，2018，378（2）： 158-168.
|
| ［27］ |
Roviello G，Villari D，Roudi R. Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk［J］.Clin Transl Oncol，2020，22（9）： 1664-1665.
|
| ［28］ |
Nishida N，Kudo M. Liver damage related to immune checkpoint inhibitors［J］.Hepatol Int，2019，13（3）： 248-252.
|
| ［29］ |
Delaunay M，Cadranel J，Lusque A，et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients［J］.Eur Respir J，2017，50（2）： 1700050.
|
| ［30］ |
Lee SH，Kim HJ，Bang HJ，et al. Case report： Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction［J］.Front Oncol，2024，14： 1273043.
|
| ［31］ |
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors： skin toxicities and immunotherapy［J］.Am J Clin Dermatol，2018，19（3）： 345-361.
|
| ［32］ |
Litton JK，Scoggins ME，Hess KR，et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant［J］.J Clin Oncol，2020，38（5）： 388-394.
|
| ［33］ |
Shatsky RA，Trivedi MS，Yau C，et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer： the sequential multiple assignment randomized I-SPY2.2 phase 2 trial［J］.Nat Med，2024，30（12）： 3737-3747.
|
| ［34］ |
Shen G，Liu Z，Wang M，et al. Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer： the phase 2 NeoSAC trial［J］.Signal Transduct Target Ther，2025，10（1）： 41.
|